feedback

Course Director

Roger S. McIntyre, MD, FRCPC
Roger S. McIntyre, MD, FRCPC

University of Toronto

Brain and Cognition Discovery Foundation (BCDF)

University Health Network

Toronto, Ontario, Canada

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME
Credit Amount:0.5 Credits
Release Date:2016-Jun-06
Expiration Date:2017-Jun-05
Estimated Time for Completion:30 minutes
Registration Required:No
Cost:Free
Activity Description and Educational Objectives
In this activity, an expert in major depressive disorder discusses the impact of cognitive symptoms and highlights potential strategies for the assessment and treatment of cognitive dysfunction in patients with this mood disorder.

Upon completion of this activity, participants should be better able to:
  • Recognize the burden of cognitive dysfunction in patients with MDD
  • Apply evidence-based approaches to assess patients with MDD for cognitive dysfunction
  • Identify treatment options for managing cognitive dysfunction in patients with MDD
Target Audience
This activity has been designed to meet the educational needs of psychiatrists, primary care physicians, and other clinicians involved in the treatment of major depressive disorder.

Requirements for Successful Completion
In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: June 06, 2016 - June 05, 2017
Time to Complete: 30 minutes

Faculty & Disclosure / Conflict of Interest Policy
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity for any amount during the past 12 months.

Course Director
Roger S. McIntyre, MD, FRCPC
Professor of Psychiatry and Pharmacology
University of Toronto
Executive Director, Brain and Cognition Discovery Foundation (BCDF)
Head, Mood Disorders Psychopharmacology Unit
University Health Network
Toronto, Ontario, Canada

Roger S. McIntyre, MD, FRCPC, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from AstraZeneca; Eli Lilly and Company; Janssen-Ortho; Lundbeck Canada Inc.; Pfizer Canada Inc.; Shire Pharma Canada ULC; The Brain & Behavior Research Foundation (Formerly The National Alliance for Research on Schizophrenia and Depression); The National Institute of Mental Health; and The Stanley Medical Research Institute.
Speakers Bureau participant with AstraZeneca; Eli Lilly and Company; Janssen-Ortho; Lundbeck Canada Inc.; Merck Canada Inc.; and Pfizer Canada Inc.
Advisory Board for AstraZeneca; Bristol-Myers Squibb Canada; Eli Lilly and Company; GlaxoSmithKline; Janssen-Ortho; Lundbeck Canada Inc.; Merck Canada Inc.; Organon Canada Ltd.; Pfizer Canada Inc.; Shire Pharma Canada ULC; and The France Foundation.

Roger S. McIntyre, MD, FRCPC, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: various therapeutic approaches for the management of cognitive symptoms in patients with MDD.

CME Reviewer
Thomas W. Heinrich, MD
Professor of Psychiatry and Family Medicine
Medical College of Wisconsin
Milwaukee, Wisconsin

Thomas W. Heinrich, MD, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director
Kirk A. Tacka, PhD
PVI, PeerView Institute for Medical Education

Kirk A. Tacka, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit & Support
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership
This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support
This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck.

Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView Press or any of its partners, providers, and/or supporters.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.